Neon Therapeutics (NASDAQ:NTGN) Trading Down 6.5%

Shares of Neon Therapeutics Inc (NASDAQ:NTGN) fell 6.5% during trading on Wednesday . The stock traded as low as $0.98 and last traded at $1.00, 673,569 shares were traded during mid-day trading. An increase of 142% from the average session volume of 277,765 shares. The stock had previously closed at $1.07.

Several brokerages recently commented on NTGN. HC Wainwright lowered Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 27th. Morgan Stanley lowered Neon Therapeutics from an “overweight” rating to a “sell” rating in a research note on Tuesday, November 26th. Zacks Investment Research lowered Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 29th. Mizuho reduced their price objective on Neon Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, Bank of America lowered Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Neon Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $10.58.

The company has a debt-to-equity ratio of 0.15, a current ratio of 4.59 and a quick ratio of 4.59. The company has a market cap of $32.31 million, a price-to-earnings ratio of -0.18 and a beta of 1.32. The business has a 50 day simple moving average of $1.75 and a 200 day simple moving average of $3.06.

Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.04). As a group, sell-side analysts anticipate that Neon Therapeutics Inc will post -2.54 earnings per share for the current fiscal year.

In other Neon Therapeutics news, insider Richard Gaynor sold 22,322 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $1.24, for a total value of $27,679.28. Following the transaction, the insider now owns 201,822 shares of the company’s stock, valued at $250,259.28. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 38.93% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC bought a new stake in shares of Neon Therapeutics during the third quarter worth $25,000. Squarepoint Ops LLC bought a new stake in shares of Neon Therapeutics during the third quarter worth $35,000. Millennium Management LLC bought a new stake in shares of Neon Therapeutics during the third quarter worth $45,000. Marshall Wace North America L.P. bought a new stake in shares of Neon Therapeutics during the first quarter worth $49,000. Finally, Westfield Capital Management Co. LP bought a new stake in shares of Neon Therapeutics during the second quarter worth $149,000. 58.19% of the stock is currently owned by institutional investors.

Neon Therapeutics Company Profile (NASDAQ:NTGN)

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: Analyzing a company’s cash flow statement

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.